The studies proposed in this Consortium build on the findings from Dr. Klimas and Dr. Sullivan’s previously funded Consortia.
There will be three Phase I clinical trials proposed, as well as two Phase II trials, that target mechanisms of energy production, inflammation, and immune function.
Specifically, based on findings from Dr. Klimas’s GWIC, Study 1 and Study 2 will evaluate a combination approach that targets inflammation and energy production using entanercept, an injectable drug that has been used in Rheumatoid Arthritis and Psoriasis, and mifepristone, a synthetic steroid.
Study 3 and 4 will be based on the findings from Dr. Sullivan’s GWIC and will determine the most effective antioxidant, CoQ10 or glutathione, in a Phase I study and then take the most effective antioxidant and combine it with intranasal insulin. Lastly,
Study 5 will evaluate a nutraceutical, Bacopa, that has been shown to have multiple impacts on inflammation, immune function, and energy production.